Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma

NCT07247383 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Marginal Zone Lymphoma of Ocular Adnexal
Marginal Zone Lymphoma(MZL)

Interventions

DRUG: Orelabrutinib (ICP-022)
RADIATION: radiotherapy
DRUG: Rituximab (R)

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University